While the hematopoietic growth factor rhu G-CSF (discussed in the Introduction) is more widely prescribed and comprises more than 95% of recombinant growth factor use, its use in infection has not demonstrated a mortality benefit in pneumonia when used in combination with antibiotic therapy (1, 4, 5, 143). Here, CSF3 is linked to infection.